Tolerability & long-term disease control by IGHV mutation status among CLL patients on ibrutinib arm of E1912.
Shanafelt TD, Wang XV, Hanson CA, Paietta E, O'Brien SM MD, Barrientos JC, Jelinek DF, Braggio E, Leis JF, Zhang C, Barr PM, Cashen AF, Mato AR, Singh AK, Mullane M, Little RF, Erba HP, Stone RM, Litzow MR, Tallman MS, Kay NE.
Shanafelt TD, et al. Among authors: barrientos jc.
Blood Adv. 2024 Aug 20:bloodadvances.2024013474. doi: 10.1182/bloodadvances.2024013474. Online ahead of print.
Blood Adv. 2024.
PMID: 39163612
No abstract available.